- Home
- AVTE vs ZYXI Comparison
AVTE vs ZYXI Comparison
Compare AVTE & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTE
- ZYXI
- Stock Information
- Founded
- AVTE 2018
- ZYXI 1996
- Country
- AVTE United States
- ZYXI United States
- Employees
- AVTE N/A
- ZYXI N/A
- Industry
- AVTE Biotechnology: Pharmaceutical Preparations
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AVTE Health Care
- ZYXI Health Care
- Exchange
- AVTE Nasdaq
- ZYXI Nasdaq
- Market Cap
- AVTE 72.5M
- ZYXI 66.5M
- IPO Year
- AVTE 2021
- ZYXI N/A
- Fundamental
- Price
- AVTE $2.75
- ZYXI $2.18
- Analyst Decision
- AVTE Hold
- ZYXI Buy
- Analyst Count
- AVTE 7
- ZYXI 3
- Target Price
- AVTE $11.75
- ZYXI $10.25
- AVG Volume (30 Days)
- AVTE 192.3K
- ZYXI 262.3K
- Earning Date
- AVTE 05-12-2025
- ZYXI 04-29-2025
- Dividend Yield
- AVTE N/A
- ZYXI N/A
- EPS Growth
- AVTE N/A
- ZYXI N/A
- EPS
- AVTE N/A
- ZYXI 0.09
- Revenue
- AVTE N/A
- ZYXI $192,354,000.00
- Revenue This Year
- AVTE N/A
- ZYXI N/A
- Revenue Next Year
- AVTE N/A
- ZYXI $23.16
- P/E Ratio
- AVTE N/A
- ZYXI $24.22
- Revenue Growth
- AVTE N/A
- ZYXI 4.36
- 52 Week Low
- AVTE $1.25
- ZYXI $1.93
- 52 Week High
- AVTE $25.29
- ZYXI $12.19
- Technical
- Relative Strength Index (RSI)
- AVTE 72.33
- ZYXI 26.14
- Support Level
- AVTE $2.61
- ZYXI $2.03
- Resistance Level
- AVTE $2.82
- ZYXI $2.24
- Average True Range (ATR)
- AVTE 0.11
- ZYXI 0.18
- MACD
- AVTE 0.02
- ZYXI 0.17
- Stochastic Oscillator
- AVTE 81.08
- ZYXI 38.46
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.